Scottish HTA says no to Roche's Avastin in ovarian cancer because of unlicensed dosing
This article was originally published in Scrip
The Scottish Medicines Consortium, Scotland's health technology appraisal body, says it cannot OK Roche's Avastin (bevacizumab) in combination with carboplatin and paclitaxel for use on the Scottish NHS for the front-line treatment of advanced ovarian cancer. The consortium said that considering the off-label 7.5mg/kg dose included in the firm's evidence, did not fall "within the SMC remit".
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.